DelveInsight’s, “Toll-Like Receptor 3 (TLR-3) Agonist - Pipeline Insight, 2022,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Toll-Like Receptor 3 (TLR-3) Agonist pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Toll-Like Receptor 3 (TLR-3) Agonist: Overview
TLR3 is a member of the toll-like receptor (TLR) family. It plays a fundamental role in pathogen recognition and activation of innate immunity. TLR3 is a nucleotide-sensing TLR which is activated by double-stranded RNA, a sign of viral infection. TLRs are highly conserved from Drosophila to humans and share structural and functional similarities. They recognize pathogen-associated molecular patterns (PAMPs) that are expressed on infectious agents, and mediate the production of cytokines necessary for the development of effective immunity. TLR3 agonist formulation are the most extensively tested as a single agent in humans with infectious diseases and cancers including glioblastoma, renal cell cancer, melanoma, leukemia, ovarian cancer, and breast cancer. In studies, TLR3 signaling is activated by a synthetic dsRNA agonist, polyriboinosinic: polyribocytidylic acid, a potent immune stimulant that has been shown to induce protective immunity against influenza, HBV, a few HIV strains and coronaviruses.
The companies and academics are working to assess challenges and seek opportunities that could influence Toll-Like Receptor 3 (TLR-3) Agonist R&D. The therapies under development are focused on novel approaches for Toll-Like Receptor 3 (TLR-3) Agonist.
This segment of the Toll-Like Receptor 3 (TLR-3) Agonist report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Toll-Like Receptor 3 (TLR-3) Agonist Emerging Drugs
Rintatolimod: AIM ImmunoTech
Rintatolimod is a synthetic derivative of inosinic acid with antiretroviral and immunomodulatory properties. Rintatolimod is a mismatched double stranded polymer of RNA. It is a restricted Toll-Like Receptor 3 (TLR3) agonist lacking activation of other primary cellular inducers of innate immunity (e.g. cytosolic helicases). Rintatolimod was granted Orphan Drug Designation by the US Food and Drug Administration (FDA) for the treatment of pancreatic cancer in December 2020.
PrEP-001: PrEP Biopharm
PrEP-001 is a nasal powder, a proprietary formulation of polyriboinosinic and polyribocytidylic acid effectively that elicits a cellular innate immune response in nasal epithelium. It is in Phase 2 for the prevention of influenza, influenza-like-illness and the common cold. PrEP-001, triggers the innate immune system through the Rig-I, MDA5 and TLR3 receptors and is expected to provide a rapid, broad-spectrum prophylaxis against ~200 respiratory viruses.
Further product details are provided in the report……..
This segment of the report provides insights about the different Toll-Like Receptor 3 (TLR-3) Agonist drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 5+ key companies which are developing the Toll-Like Receptor 3 (TLR-3) Agonist. The companies which have their Toll-Like Receptor 3 (TLR-3) Agonist drug candidates in the most advanced stage, i.e. Phase II include, AIM ImmunoTech.
DelveInsight’s report covers around 5+ products under different phases of clinical development like
Toll-Like Receptor 3 (TLR-3) Agonist pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Toll-Like Receptor 3 (TLR-3) Agonist therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Toll-Like Receptor 3 (TLR-3) Agonist drugs.
Current Scenario and Emerging Therapies:
Introduction
Executive Summary
Toll-Like Receptor 3 (TLR-3) Agonist: Overview
Pipeline Therapeutics
Therapeutic Assessment
Toll-Like Receptor 3 (TLR-3) Agonist – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Toll-Like Receptor 3 (TLR-3) Agonist Collaboration Deals
Late Stage Products (Phase III)
Drug name: Company name
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Rintatolimod: AIM ImmunoTech
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Drug name: Company name
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Products
Toll-Like Receptor 3 (TLR-3) Agonist Key Companies
Toll-Like Receptor 3 (TLR-3) Agonist Key Products
Toll-Like Receptor 3 (TLR-3) Agonist- Unmet Needs
Toll-Like Receptor 3 (TLR-3) Agonist- Market Drivers and Barriers
Toll-Like Receptor 3 (TLR-3) Agonist- Future Perspectives and Conclusion
Toll-Like Receptor 3 (TLR-3) Agonist Analyst Views
Toll-Like Receptor 3 (TLR-3) Agonist Key Companies
Appendix
List of Table
Table 1: Total Products for Toll-Like Receptor 3 (TLR-3) Agonist
Table 2: Late Stage Products
Table 3: Mid Stage Products
Table 4: Early Stage Products
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Product Type
Table 7: Assessment by Stage and Product Type
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: Inactive Products
List of Figures
Figure 1: Total Products for Toll-Like Receptor 3 (TLR-3) Agonist
Figure 2: Late Stage Products
Figure 3: Mid Stage Products
Figure 4: Early Stage Products
Figure 5: Preclinical and Discovery Stage Products
Figure 6: Assessment by Product Type
Figure 7: Assessment by Stage and Product Type
Figure 8: Assessment by Route of Administration
Figure 9: Assessment by Stage and Route of Administration
Figure 10: Assessment by Molecule Type
Figure 11: Assessment by Stage and Molecule Type
Figure 12: Inactive Products
• AIM ImmunoTech
• PrEP Biopharm
• Oncovir
• Bioncotech Therapeutics
